S100A9 and breast cancer: Our findings highlight a unique oncogenic breadth of this pathway, especially sEVs produced by invasive breast cancer cells in hypoxia (14) to globally reprogram a normal mammary epithelium (28, 29) while also introducing systemic immunosuppression via myeloid cell release of the S100A9 alarmin (21).